Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
183.92
+1.17 (0.64%)
At close: Mar 28, 2025, 4:00 PM
166.25
-17.67 (-9.61%)
After-hours: Mar 28, 2025, 7:57 PM EDT
Krystal Biotech Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Krystal Biotech stock have an average target of 220, with a low estimate of 206 and a high estimate of 245. The average target predicts an increase of 19.62% from the current stock price of 183.92.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Krystal Biotech stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 4 | 4 | 3 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 8 | 7 | 7 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Initiates $245 | Strong Buy | Initiates | $245 | +33.21% | Mar 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $221 | Strong Buy | Reiterates | $221 | +20.16% | Feb 28, 2025 |
| Citigroup | Citigroup | Hold Maintains $206 → $215 | Hold | Maintains | $206 → $215 | +16.90% | Feb 20, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $215 | Buy | Reiterates | $215 | +16.90% | Feb 20, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $212 → $218 | Strong Buy | Maintains | $212 → $218 | +18.53% | Feb 20, 2025 |
Financial Forecast
Revenue This Year
465.82M
from 290.52M
Increased by 60.34%
Revenue Next Year
686.40M
from 465.82M
Increased by 47.35%
EPS This Year
7.25
from 3.00
Increased by 141.50%
EPS Next Year
11.39
from 7.25
Increased by 57.24%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 504.8M | 901.9M | 1.2B | ||
| Avg | 465.8M | 686.4M | 843.0M | ||
| Low | 423.5M | 499.1M | 530.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 73.8% | 93.6% | 76.4% | ||
| Avg | 60.3% | 47.4% | 22.8% | ||
| Low | 45.8% | 7.1% | -22.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.77 | 16.94 | 24.81 | ||
| Avg | 7.25 | 11.39 | 14.91 | ||
| Low | 5.41 | 6.11 | 8.32 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 192.3% | 133.8% | 117.8% | ||
| Avg | 141.5% | 57.2% | 30.9% | ||
| Low | 80.3% | -15.7% | -27.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.